Ophthalmic drug delivery systems

Singh, K., and Mezei, M. (1983). Liposomal ophthalmic drug delivery system. I. Triamcinolon acetonide, Int. J. Pharm., 16,... 

An erodible insert developed as a potential ocular drug-delivery system is marketed as a prescription drug for the lubricant properties of the polymer base. Lacrisert is a sterile ophthalmic insert used in the treatment of moderate to severe dry eye syndrome and is usually recommended for patients unable to obtain symptomatic relief with artificial tear solutions. The insert is composed of 5 mg of hydroxypropylcellulose in a rod-shaped form about 1.27 mm diameter by about 3.5 mm long. No preservative is used, since it is essentially anhydrous. The quite rigid cellulose rod is placed in the lower conjunctival sac and first imbibes water from the tears and after several hours forms a... 

J. R. Robinson, ed. Ophthalmic Drug Delivery Systems, Academy of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, DC, 1980. 

Ophthalmic Drug Delivery Systems, edited by Ashim K. Mitra... 

SD Alani. (1990). The ophthalmic rod—A new ophthalmic drug delivery system. I. Graefes Arch Clin Exp Ophthalmol 228 297-301. 

VHL Lee. (1993). Precorneal, corneal, and postcorneal factors. In AK Mitra, ed. Ophthalmic Drug Delivery Systems. New York Marcel Dekker, pp 59-81. 

Schiraldi et al. [64] have developed this kind of material by combining silica particles and pHEMA. pHEMA is a biocompatible hydrogel that has been widely studied in the past decades due to its chemical-physical structure and mechanical properties. It has been widely used in ophthalmic prostheses (contact or intraocular lenses), vascular prostheses, drug delivery systems and soft-tissue replacement [65]. These authors have shown that by incorporating silica nanoparticles, the resulting hybrid material is highly biocompatible and promotes bone cell adhesion and proliferation of bone cells seeded on it.1 ... 

Operations improvement, waste minimization via, 25 884t Ophthalmic drug delivery systems, 18 711 Ophthalmic drug dosage forms, 18 716 Ophthalmic solutions, ethylene oxide polymers in, 10 687 Opiates, economic aspects, 2 108 Opium, 2 89-90... 

Ophthalmic Drug Delivery Systems Second Edition, Revised and Expanded, edited byAshim K Mitra... 

Pharmaceutical Process Validation Second Edition, Revised and Expanded, edited by Ira R. Berry and Robert A. Nash Ophthalmic Drug Delivery Systems, edited by Ashim K. Mitra Pharmaceutical Skin Penetration Enhancement, edited by Kenneth A. Walters and Jonathan Hadgraft... 

Ahmed, I. 2003. The noncorneal route in ocular drug delivery. In Ophthalmic Drug Delivery Systems, ed. A.K. Mitra. 335. Marcel Dekker, New York. 

Shell, J.W. 1984. Ophthalmic drug delivery systems. Surv Ophthalmol 29 117. 

Myles, M.E., et al. 2003. Ocular iontophoresis. In Ophthalmic drug delivery systems, 2nd ed., ed. A.K. Mitra, 365. New York Marcel Dekker. 

Cohen, S., Lobel, E., Trevgoda, A., and Peled, T. (1997), A novel in situ—forming ophthalmic drug delivery system from alginates undergoing gelation in the eye, / Controlled Release, 44, 201-208. 

Although conventional eye drops still represent about 90% of all marketed ophthalmic dosage forms, there have been significant efforts towards the development of new drug delivery systems. 

Only a few of these new ophthalmic drug delivery systems have been commercialized over the past decades, but research in the different areas of ocular drug delivery has provided important impetus and dynamism, with the promise of some new and exciting developments in the held. 

Jumbe, N. L., and Miller, M. H. (2003), Ocular drug transfer following systemic drug administration, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, 2nd ed., Marcel Dekker, New York, pp. 109-133. 

Lele, B. S., and Hoffman, A. S. (2000), Insoluble ionic complexes of polyacrylic acid with a cationic drug for use as a mucoadhesive, ophthalmic drug delivery system,/. Biomater. 

---